New group vice president, pharmaceutical sciences and manufacturing operations for Biovail

Toronto, ON June 20, 2003 Praveen Tyle, PhD, has been appointed group vice president, pharmaceutical sciences and manufacturing, effective immediately of Biovail. Dr Tyle will be responsible for directing the company’s global product development activities as well as commercial manufacturing operations.

Dr Tyle will report to Gregory Szpunar, PhD senior vice president, research and development and chief scientific officer. Dr Tyle brings over 19 years of drug development and commercialization experience to Biovail. He joins Biovail from Pharmacia (now Pfizer) where he most recently served as vice president and global head of pharmaceutical sciences. Dr Tyle had joined the predecessor company Pharmacia & Upjohn in 1999 from Aronex Pharmaceuticals where he was senior vice president, development and operations, and chief technical officer. Dr Tyle has also worked at Agouron Pharmaceuticals (now Pfizer) as head of pharmaceutical development and quality assurance from 1991-1997; Sandoz Pharmaceuticals (now Novartis) from 1987-91; and American Cyanamid Company (now Wyeth) from 1984-87.

His tenure in the industry includes building, participation in and responsibility for directing global research and development activities ranging from pre-clinical development through commercialization for prescription, consumer health and animal health products.

A holder of several patents, author of over 120 presentations and publications, and editor of seven books in the area of drug development, Dr Tyle holds a PhD in pharmaceutics and pharmaceutical chemistry from Ohio State University, and a bachelor of pharmacy (honors) from the Institute of Technology, Banaras Hindu University, India. He serves on the board of directors of Orient Europharma, Taiwan and Interpath Pharmaceuticals, Houston, and as an adjunct professor of pharmacy at the University of Houston and the University of Rhode Island.